Daiwa Securities Group
ABCL icon

Daiwa Securities Group’s AbCellera Biologics ABCL Stock Holding History

Daiwa Securities Group’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.41M Buy
+561,500
New +$2.74M 0.01% 540

Other funds holding ABCL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
TWC
TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Daiwa Securities Group's ABCL Position: Q2 2026 in Review

Daiwa Securities Group opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 311,500 shares worth $2.45M. The stake represents ﹤0.01% of the portfolio and ranks #653 among its holdings. This is a return to the name: Daiwa Securities Group previously reported a position in ABCL as recently as Q4 2025.

Daiwa Securities Group first reported a position in ABCL in Q4 2021 and has held it in 18 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Daiwa Securities Group held 311,500 shares of AbCellera Biologics worth $2.45M as of Q2 2026.
  • AbCellera Biologics was a new Daiwa Securities Group position in Q2 2026.
  • AbCellera Biologics made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #653 holding.
  • Daiwa Securities Group first reported a position in AbCellera Biologics in Q4 2021 and has held it in 18 quarters since.
  • 150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.